Covance, M2Gen Aim to Improve Patient Recruitment for Oncology Trials | GenomeWeb

NEW YORK (GenomeWeb News) – Drug development service company Covance today announced an alliance and service agreement with M2Gen to match patients for biomarker-driven oncology trials with the right treatment or clinical trial.

Under the terms of the deal, Covance will be the preferred provider for M2Gen for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be done at Covance's genomics laboratory in Seattle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.